Minnelide reduces tumor burden in preclinical models of osteosarcoma

Sulagna Banerjee, Venugopal Thayanithy, Veena Sangwan, Tiffany N. Mackenzie, Ashok K Saluja, Subree Subramanian

Research output: Contribution to journalArticlepeer-review

44 Scopus citations


Osteosarcoma is the most common bone cancer in children and adolescents with a 5-year survival rate of about 70%. In this study, we have evaluated the preclinical therapeutic efficacy of the novel synthetic drug, Minnelide, a prodrug of triptolide on osteosarcoma. Triptolide was effective in significantly inducing apoptosis in all osteosarcoma cell lines tested but had no significant effect on the human osteoblast cells. Notably, Minnelide treatment significantly reduced tumor burden and lung metastasis in the orthotopic and lung colonization models. Triptolide/Minnelide effectively downregulated the levels of pro-survival proteins such as heat shock proteins, cMYC, survivin and targets the NF-κB pathway.

Original languageEnglish (US)
Pages (from-to)412-420
Number of pages9
JournalCancer Letters
Issue number2
StatePublished - Jul 28 2013

Bibliographical note

Funding Information:
This study was supported by grants R01CA124723 and R01CA170496 from the NIH (A.K.S.), by a Faculty Research and Development grant from the University of Minnesota Academic Health Center, by a translational research grant from the Masonic Cancer Center, University of Minnesota, by grants from the Wyckoff Rein in Sarcoma (S.S.).


  • Heat shock proteins
  • Minnelide
  • NF-κB
  • Osteosarcoma
  • Triptolide


Dive into the research topics of 'Minnelide reduces tumor burden in preclinical models of osteosarcoma'. Together they form a unique fingerprint.

Cite this